《瑞信窩輪》車股回穩藥明反彈,留意小鵬購26298、藥明牛57153
比亞迪股份(1211)周一曾逆市升約2%,高見260元以上,其後窄幅爭持。向上留意重上270元水平的機會,250元水平觀望可否構建支持。看好可留意比迪購23873,行使價269.08元,24年3月到期。
小鵬汽車(9868)曾飆逾6%,高位突破42元,其後保持在40元以上靠穩。向上留意上試一個月高位46.7元的機會,38元水平或具支持。看好可留意小鵬購26298,行使價59.55元,23年11月到期。
藥明生物(2269)終反彈,高位曾漲逾4%,但未能成功突破40元關口。向上觀望重上並企穩40元的機會,支持或參考去年10月底低位35元水平。看好可留意藥明購27754,行使價46.05元,23年12月到期。或藥明牛57153,收回價33.88元,行使價32.38元,23年7月到期。
康方生物(9926)曾高見35元以上,升幅超過6%,一舉突破10天、20天和250天線。看好可留意康方購28102,行使價35.88元,23年12月到期。
信達生物(1801)四連跌後,周一曾升逾3%至31.5元。看好可留意信藥購27884,行使價38.93元,23年12月到期。
以上產品資料來源: 彭博資訊及瑞信網站cswarrants.com
(本結構性產品並無抵押品)
《瑞信香港認股證及牛熊證銷售主管何啟聰》
免責聲明:筆者為瑞士信貸(香港)有限公司的代表,為證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能為零。有關恆生指數,恆生中國企業指數或恆生科技指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司Credit Suisse Securities (Hong Kong) Limited為結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.